References: 1. The Pharmaceutical Benefits Scheme (PBS). PBS website. https://www.pbs.gov.au Accessed June 2026. 2. FORXIGA® Approved Product Information 3. Kidney Health Australia, Chronic Kidney Disease (CKD) Management in Primary Care (5th edition) 2024.  Available at: CKD management handbook | Kidney Health Australia Accessed June 2026.

The DAPA-CKD trial1,8,9

Randomised, double-blind, placebo-controlled, multicentre Phase III trial1,8,9

Adapted from Supplement to: Heerspink et al. 2020.8

‡ESKD defined as the need for maintenance dialysis for at least 28 days, renal transplantation or sustained eGFR <15 mL/min/1.73 m2 for at least 28 days.1 *PACD (i.e. date when the predetermined number of adjudicated primary events are anticipated) was April 3 2020, the cut-off date for all efficacy analysis8; †SoC included ACEi/ARB.1

References: 1. FORXIGA® Approved Product Information. 2. Heerspink HJL et al. N Engl J Med. 2020;383(15):1436–1446. 3. The EMPA-KIDNEY Collaborative Group; Herrington WG et al. N Engl J Med. 2023;388(2):117–127. 4. McMurray JJV et al. N Engl J Med. 2019;381(21):1995–2008. 5. EMPEROR-Reduced Trial Investigators; Packer M et al. N Engl J Med. 2020;383(15):1413–1424. 6. Jhund PS et al. Nat Med. 2022;28(9):1956–1964. 7. Solomon SD et al. N Engl J Med. 2022;387(12):1089–1098. 8. Supplement to: Heerspink HJL et al. N Engl J Med. 2020;383(15):1436–1446. 9. Wheeler DC et al. Nephrol Dial Transplant. 2020;35(10):1700–1711.

Help delay dialysis – initiate FORXIGA® earlier1,2

Extrapolated data provides insightful evidence, but robust conclusions should not be deduced on the specific time frame delayed in the absence of clinical studies. These estimates do not consider competing risk of death, and they assume that adherence is maintained, that benefits are sustained over time, and that there are no longer-term adverse effects.1,2

References: 1. Heerspink HJL et al. Lancet Diabetes Endocrinol. 2021;9(11):743–754. 2. Madero M et al. Kidney Med. 2024;6(8):100851.

FORXIGA® – simple dosing for your patients1

References: 1. FORXIGA® Approved Product Information. 2. The Pharmaceutical Benefits Scheme (PBS). PBS website. https://www.pbs.gov.au Accessed June 2026.

CKD Mortality Evidence

Overview of FORXIGA® proteinuric CKD mortality and renal outcomes across the DAPA-CKD trial.

CKD Indication and Efficacy Summary

Overview of FORXIGA® proteinuric CKD clinical evidence, indication and dosing guide.

CKD Patient booklets

Patient resource for your CKD patients prescribed FORXIGA®

Unmatched Mortality Evidence

Overview of Forxiga’s mortality and cardiorenal outcomes across DAPA-CKD, DAPA-HF, and DELIVER (including pooled analyses)

DAPA-CKD trial summary

Forxiga efficacy and safety in CKD, key endpoints and subgroup results, absolute and relative risk reductions, NNT, and study design parameters

CKD Patient Tear-off Resource 

A tear-off sheet for patients prescribed FORXIGA® for CKD that supports patient understanding and adherence at the point of prescribing. This resource includes how to take it, sick day rules, potential side effects and when to pause/restart around illness or surgery.

CVRM Hub

Explore resources for the management of
cardiovascular, renal and metabolic diseases

Forxiga® Samples


Samples available to order today for your
eligible patients

FORXIGA® – clinical considerations1

Please refer to FORXIGA® Approved Product Information for a complete list of contraindications, special warnings and precautions for use and adverse effects.

FORXIGA® – well-established safety profile1-8

across all indications

*In the DECLARE study, risk factors for cardiovascular disease included: age ≥55 years in men or ≥60 years in women and one or more of dyslipidaemia, hypertension or current tobacco use, without having had a CV event at baseline.8 †Acute kidney injury.8 ‡Major hypoglycaemia was defined in DAPA-CKD and DELIVER as hypoglycaemia with the following criteria, confirmed by the investigator: symptoms of severe impairment in consciousness or behaviour, need for external assistance, use of an intervention to treat hypoglycaemia, and prompt recovery of acute symptoms following the intervention.2,7 Major hypoglycaemia was defined in DECLARE and DAPA-HF as hypoglycaemia requiring the assistance of another person to actively administer carbohydrates or glucagon or to take other corrective action. All cases occurred in patients with diabetes at baseline.4,8 §Serious adverse event. ¶HFrEF defined as NYHA class II–IV HF and ejection fraction of ≤40%.4 **HFpEF defined as NYHA class II-IV HF and LVEF >40%;6 ^Serious adverse events or adverse events leading to discontinuation.8 ¥A total of 10 patients (5 in the dapagliflozin group and 5 in the placebo group) were excluded from the safety analyses because they did not receive any dose of dapagliflozin or placebo. Safety outcomes were events with an onset date on or after the date of the first dose and up to and including 30 days after the last dose of dapagliflozin or placebo;6 ††Any SAE or AE that led to discontinuation of dapagliflozin or placebo that was suggestive of volume depletion;6 ‡‡Any renal SAE or AE that led to discontinuation of dapagliflozin or placebo.6

References: 1. FORXIGA® Approved Product Information. 2. Wiviott SD et al. N Engl J Med. 2019;380:347–357. 3. Heerspink HJL et al. N Engl J Med. 2020;383(15):1436–1446. 4. Supplement to: Heerspink HJL et al. N Engl J Med. 2020;383(15):1436–1446. 5. McMurray JJV et al. N Engl J Med. 2019;381(21):1995–2008. 6. Supplement to: McMurray JJV et al. N Engl J Med. 2019;381(21):1995–2008. 7. Solomon SD et al. N Engl J Med 2022;387:1089–1098. 8. Supplement to: Solomon SD et al. N Engl J Med. 2022;387(12):1089–1098.

Need more information?

AstraZeneca and the Forxiga team are committed to supporting you and your patients. If you would like further information or have a request for resources not currently available, please request a rep visit below.

PLEASE CLICK HERE TO REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.
FURTHER INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA.

PBS Information: FORXIGA®: Authority Required (STREAMLINED): Type 2 Diabetes, Chronic Heart Failure and Chronic Kidney Disease. Refer to PBS Schedule for full Authority Required Information.

FORXIGA® is a registered trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https://contactazmedical.astrazeneca.com. Date of preparation: September 2026, AU-26012

Study details1,2

The data presented here is an extrapolation of a pre-specified analyses of eGFR slope from the DAPA-CKD clinical trial. 

The decline in kidney function over time (eGFR slope) is on the causal pathway to kidney failure. Emerging evidence supports the eGFR slope as a viable surrogate for kidney failure in clinical trials of chronic kidney disease progression. Based on this, the aim of this prespecified analyses of the DAPA-CKD trial was to assess the effect of dapagliflozin on eGFR slope by establishing the effect of dapagliflozin on changes in eGFR during the acute phase (ie, from baseline to week 2 of treatment), chronic phase (ie, from week 2 to end of treatment), and total eGFR slope (from baseline to end of treatment full cohort). In the full cohort, dapagliflozin compared with placebo reduced the rate of eGFR decline from baseline to end of treatment by 0.95 mL/min per 1.73m2.

Extrapolation data are projections based on the eGFR from week 2 to end of treatment (DAPA-CKD chronic phase) and assume linear progression of eGFR decline. Initial eGFR decline over the first 2 weeks was estimated using eGFR slope data from the acute phase of the DAPA-CKD (baseline to week 2). 

Example patient with initial eGFR of 30 mL/min/1.73m2 used eGFR slope data from the DAPA-CKD trial subgroup with eGFR <45 mL/min/1.73m2; eGFR at the start of the chronic phase: FORXIGA®, 27.4 mL/min/1.73m2; placebo, 29.6 mL/min/1.73m2. Example patient with initial eGFR of 60 mL/min/1.73m2 used eGFR slope data from the DAPA-CKD trial subgroup with eGFR ≥ 45 mL/min/1.73m2; eGFR at the start of the chronic phase: FORXIGA®, 56.3 mL/min/1.73m2; placebo, 59.0 mL/min/1.73m2.